SUMMER STANTON: Open Payments
NPI 1023505815 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,143 in 60 payments from 15 companies in 2025. Trend: 2023 $945 · 2024 $1,052 · 2025 $1,143
Food & beverage: $1,143
| Company | Payments | Amount |
|---|---|---|
| 180 Medical, Inc. | 10 | $163 |
| UROGEN PHARMA, INC. | 9 | $162 |
| PFIZER INC. | 9 | $140 |
| ABBVIE INC. | 5 | $119 |
| Janssen Biotech, Inc. | 7 | $117 |
| Ferring Pharmaceuticals Inc. | 3 | $96 |
| Merck Sharp & Dohme LLC | 4 | $68 |
| TOLMAR, INC. | 3 | $62 |
| Boston Scientific Corporation | 2 | $50 |
| Teleflex LLC | 2 | $49 |
Products named: XTANDI, ERLEADA, LUPRON DEPOT, ADSTILADRIN, JELMYTO, KEYTRUDA, JATENZO, ZUSDURI.
Industry payments across NE — which companies pay providers there.
